Us Bancorp \De\ Nektar Therapeutics Transaction History

Us Bancorp \De\

$75.6 Billion
Q4 2024

A detailed history of Us Bancorp \De\ transactions in Nektar Therapeutics stock. As of the latest transaction made, Us Bancorp \De\ holds 14,000 shares of NKTR stock, worth $14,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

14,000

Previous 17,000 17.65%

Holding current value

$14,000

Previous $22,000 40.91%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 05, 2025	SELL	$0.9 - $1.45 $2,700 - $4,350	-3,000 Reduced 17.65%	14,000 $13,000
Q2 2024 Aug 06, 2024	BUY	$0.9 - $1.83 $15,300 - $31,110	17,000 New	17,000 $21,000
Q2 2023 Aug 09, 2023	SELL	$0.53 - $1.03 $4,589 - $8,919	-8,660 Reduced 14.53%	50,950 $29,000
Q1 2023 May 09, 2023	SELL	$0.64 - $3.15 $1,432 - $7,052	-2,239 Reduced 3.62%	59,610 $41,000
Q4 2022 Feb 13, 2023	SELL	$2.03 - $4.28 $10,391 - $21,909	-5,119 Reduced 7.64%	61,849 $139,000
Q3 2022 Oct 27, 2022	SELL	$3.04 - $5.14 $7,682 - $12,988	-2,527 Reduced 3.64%	66,968 $215,000
Q2 2022 Aug 01, 2022	SELL	$3.17 - $6.17 $520,960 - $1.01 Million	-164,341 Reduced 70.28%	69,495 $264,000
Q1 2022 May 11, 2022	BUY	$4.16 - $13.72 $6,730 - $22,198	1,618 Added 0.7%	233,836 $1.26 Million
Q4 2021 Feb 11, 2022	SELL	$10.83 - $18.41 $164,009 - $278,801	-15,144 Reduced 6.12%	232,218 $3.14 Million
Q3 2021 Nov 10, 2021	SELL	$13.07 - $18.84 $299,316 - $431,454	-22,901 Reduced 8.47%	247,362 $4.44 Million
Q2 2021 Aug 05, 2021	BUY	$16.52 - $20.4 $16,007 - $19,767	969 Added 0.36%	270,263 $4.64 Million
Q1 2021 Apr 28, 2021	SELL	$16.56 - $25.46 $94,888 - $145,885	-5,730 Reduced 2.08%	269,294 $5.39 Million
Q4 2020 Feb 04, 2021	BUY	$15.77 - $19.03 $1.35 Million - $1.64 Million	85,921 Added 45.44%	275,024 $4.68 Million
Q3 2020 Nov 10, 2020	BUY	$16.59 - $24.79 $1.68 Million - $2.51 Million	101,122 Added 114.94%	189,103 $3.14 Million
Q2 2020 Aug 07, 2020	SELL	$16.86 - $23.44 $2,360 - $3,281	-140 Reduced 0.16%	87,981 $2.04 Million
Q1 2020 May 13, 2020	BUY	$14.47 - $27.96 $7,336 - $14,175	507 Added 0.58%	88,121 $1.57 Million
Q4 2019 Feb 04, 2020	SELL	$15.87 - $23.12 $1,428 - $2,080	-90 Reduced 0.1%	87,614 $1.89 Million
Q3 2019 Nov 08, 2019	SELL	$16.91 - $36.27 $1,352 - $2,901	-80 Reduced 0.09%	87,704 $1.6 Million
Q2 2019 Aug 13, 2019	BUY	$31.0 - $36.3 $18,042 - $21,126	582 Added 0.67%	87,784 $3.12 Million
Q1 2019 May 08, 2019	BUY	$31.58 - $46.35 $1,168 - $1,714	37 Added 0.04%	87,202 $2.93 Million
Q4 2018 Feb 13, 2019	BUY	$30.43 - $56.65 $182 - $339	6 Added 0.01%	87,165 $2.87 Million
Q3 2018 Nov 01, 2018	SELL	$46.46 - $68.49 $1,626 - $2,397	-35 Reduced 0.04%	87,159 $5.31 Million
Q2 2018 Aug 08, 2018	SELL	$46.25 - $104.45 $7,215 - $16,294	-156 Reduced 0.18%	87,194 $4.26 Million
Q1 2018 May 08, 2018	BUY	$57.4 - $108.44 $574 - $1,084	10 Added 0.01%	87,350 $9.28 Million
Q4 2017 Feb 02, 2018	SELL	$23.02 - $60.5 $138,120 - $363,000	-6,000 Reduced 6.43%	87,340 $5.22 Million
Q3 2017 Nov 13, 2017	BUY	$17.79 - $24.0 $1.66 Million - $2.24 Million	93,340	93,340 $2.24 Million

Others Institutions Holding NKTR

# of Institutions

152

Shares Held

131M

Call Options Held

92.7K

Put Options Held

4.9K

View Full List

About NEKTAR THERAPEUTICS

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $187M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

More about NKTR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account